From the Analyst's Couch | Published:

Reforming China's drug regulatory system

Nature Reviews Drug Discovery volume 17, pages 858859 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

  1. Fudan Center for Study of Pharmaceuticals and Healthcare Strategy, Pudong, Shanghai, China.

    • Lili Xu
    •  & Liming Shao
  2. Shanghai Association of Food and Drug Safety, Xuhui, Shanghai, China.

    • Huijun Gao
  3. Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA.

    • Kenneth I. Kaitin

Authors

  1. Search for Lili Xu in:

  2. Search for Huijun Gao in:

  3. Search for Kenneth I. Kaitin in:

  4. Search for Liming Shao in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Liming Shao.

Supplementary information

PDF files

  1. 1.

    Supplementary information

    China's drug regulatory system reform timeline (May 2015 to May 2018)*

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.150

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing